GMP manufacture of Shigella flexneri 2a Artificial Invaplex (InvaplexAR) and evaluation in a Phase 1 Open-label, dose escalating study administered intranasally to healthy, adult volunteers

Duplessis, Christopher; Clarkson, Kristen A.; Ross Turbyfill, K.; Alcala, Ashley N.; Gutierrez, Ramiro; Riddle, Mark S.; Lee, Tida; Paolino, Kristopher; Weerts, Hailey P.; Lynen, Amanda; Oaks, Edwin V.; Porter, Chad K.; Kaminski, Robert

doi:10.1016/j.vaccine.2023.08.051

Cited by 1 publication

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was also able to induce robust systemic and mucosal immune responses in Phase 1 studies [102]. This vaccine candidate has also undergone a successful cGMP manufacturing feasibility study and can be manufactured to exhibit an expanded serotype coverage [103,104].…”

Section: Lps-based Vaccinesmentioning

confidence: 99%

Shigella Vaccines: The Continuing Unmet Challenge

Lu,

Das,

Howlader

et al. 2024

IJMS

View full text Add to dashboard Cite

Shigellosis is a severe gastrointestinal disease that annually affects approximately 270 million individuals globally. It has particularly high morbidity and mortality in low-income regions; however, it is not confined to these regions and occurs in high-income nations when conditions allow. The ill effects of shigellosis are at their highest in children ages 2 to 5, with survivors often exhibiting impaired growth due to infection-induced malnutrition. The escalating threat of antibiotic resistance further amplifies shigellosis as a serious public health concern. This review explores Shigella pathology, with a primary focus on the status of Shigella vaccine candidates. These candidates include killed whole-cells, live attenuated organisms, LPS-based, and subunit vaccines. The strengths and weaknesses of each vaccination strategy are considered. The discussion includes potential Shigella immunogens, such as LPS, conserved T3SS proteins, outer membrane proteins, diverse animal models used in Shigella vaccine research, and innovative vaccine development approaches. Additionally, this review addresses ongoing challenges that necessitate action toward advancing effective Shigella prevention and control measures.

show abstract

Section: Lps-based Vaccinesmentioning

confidence: 99%